JP2018528783A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528783A5
JP2018528783A5 JP2018515456A JP2018515456A JP2018528783A5 JP 2018528783 A5 JP2018528783 A5 JP 2018528783A5 JP 2018515456 A JP2018515456 A JP 2018515456A JP 2018515456 A JP2018515456 A JP 2018515456A JP 2018528783 A5 JP2018528783 A5 JP 2018528783A5
Authority
JP
Japan
Prior art keywords
duplex
modified
modified oligonucleotide
extrahepatic
section
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018515456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528783A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/053836 external-priority patent/WO2017053999A1/en
Publication of JP2018528783A publication Critical patent/JP2018528783A/ja
Publication of JP2018528783A5 publication Critical patent/JP2018528783A5/ja
Pending legal-status Critical Current

Links

JP2018515456A 2015-09-25 2016-09-26 コンジュゲートアンチセンス化合物及びその使用 Pending JP2018528783A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233292P 2015-09-25 2015-09-25
US62/233,292 2015-09-25
PCT/US2016/053836 WO2017053999A1 (en) 2015-09-25 2016-09-26 Conjugated antisense compounds and their use

Publications (2)

Publication Number Publication Date
JP2018528783A JP2018528783A (ja) 2018-10-04
JP2018528783A5 true JP2018528783A5 (enExample) 2019-11-07

Family

ID=58387451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515456A Pending JP2018528783A (ja) 2015-09-25 2016-09-26 コンジュゲートアンチセンス化合物及びその使用

Country Status (4)

Country Link
US (2) US11116843B2 (enExample)
EP (1) EP3353306A4 (enExample)
JP (1) JP2018528783A (enExample)
WO (1) WO2017053999A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11433089B2 (en) 2016-09-23 2022-09-06 National University Corporation Tokyo Medical And Dental University Blood-brain barrier permeable heteroduplex nucleic acid
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
EP3684378A4 (en) * 2017-09-19 2021-06-16 Children's National Medical Center GAPMERS AND THEIR USES IN THE TREATMENT OF MUSCLE DYSTROPHY
WO2019118916A1 (en) * 2017-12-14 2019-06-20 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
MY203356A (en) 2018-01-12 2024-06-25 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019140236A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019165067A1 (en) 2018-02-21 2019-08-29 Bristol-Myers Squibb Company Camk2d antisense oligonucleotides and uses thereof
EP3766972B1 (en) 2018-03-14 2025-04-23 Institute of Science Tokyo Nucleic acid complex
KR20190110043A (ko) * 2018-03-19 2019-09-27 주식회사 케이티 비디오 신호 처리 방법 및 장치
US11851654B2 (en) * 2018-03-19 2023-12-26 National University Corporation Tokyo Medical And Dental University Nucleic acid with reduced toxicity
JP7262816B2 (ja) * 2018-03-22 2023-04-24 国立大学法人 東京医科歯科大学 ヘテロ核酸のbbb通過脂質リガンド
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2020072991A1 (en) * 2018-10-05 2020-04-09 Ionis Pharmaceuticals, Inc. Modified oligomeric compounds and uses thereof
TW202104595A (zh) * 2019-03-29 2021-02-01 日商田邊三菱製藥股份有限公司 用來調節dux4的表現之化合物、方法及醫藥組成物
CN113677374A (zh) * 2019-04-08 2021-11-19 国立大学法人东京医科齿科大学 肌疾病治疗用药物组合物
WO2021054370A1 (ja) * 2019-09-18 2021-03-25 国立大学法人東京医科歯科大学 核酸複合体
EP4043565A4 (en) * 2019-10-11 2024-01-24 National University Corporation Tokyo Medical and Dental University MODIFIED HETERONUCLEIC ACID
WO2021092371A2 (en) * 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
EP4087653A4 (en) * 2020-01-10 2024-06-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3192884A1 (en) * 2020-09-04 2022-03-10 The University Of Chicago Nucleic acid-derivatized therapeutics
CN116333013B (zh) * 2020-09-30 2025-09-02 纳肽得(青岛)生物医药有限公司 一种靶向配体
AU2021382146A1 (en) 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
AR124713A1 (es) * 2021-01-28 2023-04-26 Dicerna Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión de genes en el sistema nervioso central
CN117015384A (zh) * 2021-03-05 2023-11-07 戴瑟纳制药公司 Rnai缀合物及其用途
IL305634A (en) * 2021-03-05 2023-11-01 Dicerna Pharmaceuticals Inc Rnai conjugates and uses thereof
IL315546A (en) 2022-03-16 2024-11-01 Empirico Inc GALNAC compositions to improve siRNA bioavailability
EP4499834A2 (en) 2022-03-28 2025-02-05 Empirico Inc. Modified oligonucleotides
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
EP4522742A2 (en) 2022-05-13 2025-03-19 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024238385A2 (en) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
TW202508607A (zh) * 2023-05-19 2025-03-01 大陸商北京炫景瑞醫藥科技有限公司 雙股寡核苷酸及其共軛物和用途
WO2024257861A1 (ja) * 2023-06-16 2024-12-19 日産化学株式会社 脂質結合オリゴヌクレオチド又はその複合体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
EP2239328A3 (en) 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Methods and compositions for treating neurological disease
US8507455B2 (en) * 2007-12-04 2013-08-13 Alnylam Pharmaceuticals, Inc. Folate conjugates
US20100048676A1 (en) 2008-08-04 2010-02-25 University Of Rochester Non-androgen dependent roles for androgen receptor in liver cancer
US20100222417A1 (en) 2008-11-26 2010-09-02 Alnylam Pharmaceuticals Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues
HUE026280T2 (en) * 2009-02-12 2016-06-28 Curna Inc Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
ES2756326T3 (es) 2010-07-19 2020-04-27 Ionis Pharmaceuticals Inc Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
HK1200484A1 (zh) * 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
CN104126010B (zh) 2011-12-16 2021-04-06 国立大学法人东京医科齿科大学 嵌合的双链核酸
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
WO2014132671A1 (en) 2013-03-01 2014-09-04 National University Corporation Tokyo Medical And Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
JP6472087B2 (ja) 2013-05-30 2019-02-27 国立大学法人 東京医科歯科大学 治療用オリゴヌクレオチドを送達するための二本鎖剤
CN105324119A (zh) 2013-06-16 2016-02-10 国立大学法人东京医科齿科大学 具有外显子跳跃效应的双链反义核酸
TW201536329A (zh) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
WO2015183943A2 (en) * 2014-05-27 2015-12-03 Trustees Of Boston University Inhibitors of fibroproliferative disorders and cancer
EP3180426B1 (en) * 2014-08-17 2019-12-25 The Broad Institute, Inc. Genome editing using cas9 nickases
EP3353305A4 (en) 2015-09-25 2019-09-18 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use

Similar Documents

Publication Publication Date Title
US11116843B2 (en) Conjugated antisense compounds and their use
RU2501803C2 (ru) Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)
JP5763539B2 (ja) 5’及び2’ビス置換ヌクレオシド及びそれから製造されるオリゴマー化合物
US9428750B2 (en) Oligomeric compounds comprising tricyclic nucleosides and methods for their use
CN110846316B (zh) 在基因沉默中具有降低的脱靶效应的una寡聚物
RU2015151199A (ru) Сопряженные антисмысловые соединения и их применение
JP2021072862A (ja) B型肝炎感染の治療用のPAPD5及びPAPD7 mRNAを低減させるための核酸分子
CN117813383B (zh) 用于抑制CIDEB基因表达的siRNA、药物及其应用
US9249178B2 (en) Tricyclic nucleosides and oligomeric compounds prepared therefrom
KR20200104347A (ko) 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드
EP3516062A1 (en) Myostatin irna compositions and methods of use thereof
JP2026074094A (ja) Fubp1発現を調節するための増強されたオリゴヌクレオチド
US20250263703A1 (en) Linkage Modified Oligomeric Compounds
US20160186174A1 (en) Substituted morpholino compounds analogs thereof and oligomeric compounds prepared therefrom
WO2021157730A1 (ja) 核酸医薬とその使用
US20220098595A1 (en) Nr2e3 expression reducing oligonucleotides, compositions containing the same, and methods of their use
WO2022266486A2 (en) Products and compositions
EP3914713A1 (en) Nrl expression reducing oligonucleotides, compositions containing the same, and methods of their use
JPWO2021002359A1 (ja) 核酸医薬とその使用
US20250368998A1 (en) Nucleotide analogues, and preparation and application thereof
CN121592647A (zh) dsRNA分子、药物组合物及其在肝外递送中的应用
WO2026009916A1 (ja) 2本鎖オリゴヌクレオチド
DE102022124232A1 (de) Antisense-Oligonukleotide für die Behandlung des Joubert-Syndroms
WO2024257861A1 (ja) 脂質結合オリゴヌクレオチド又はその複合体
JP2024505583A (ja) Rtel1発現を阻害するための増強されたオリゴヌクレオチド